Chongqing Pharscin Pharmaceutical Co., Ltd.

Equities

002907

CNE100003308

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
13.31 CNY -0.30% Intraday chart for Chongqing Pharscin Pharmaceutical Co., Ltd. +3.98% -13.85%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pharscin Pharma Gets License to Produce Olmesartan Medoxomil Amlodipine Tablets MT
Pharscin Pharmaceutical Amends Colon Cleanser Drug's Validity Period MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Pharscin Pharmaceutical Gets FDA Nod on Buspirone Hydrochloride Tablets MT
Chongqing Pharscin Pharmaceutical Co., Ltd.(XSEC:002907) added to S&P Global BMI Index CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Pharscin Pharmaceutical Gets Nod to Amend Usage of Bawei Qilong Granules MT
Pharscin Pharma's Production Base Passes US FDA Inspection MT
Pharscin Pharma Gets Approval for Supplementary Application of Traditional Chinese Medicine MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Pharscin Pharma Obtains China Marketing Rights to Hypertension Drug; Shares Drop 4% MT
Pharscin Pharma’s Profit Rises 3.5% in 2022 Despite 7% Drop in Revenue MT
Chengxin Rating Terminates Pharscin Pharma’s Credit Ratings After Bond Redemption MT
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Announces Board Changes CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Chengdu Shangyi Information Technology Co., Ltd. announced that it has received $15.45 million in funding from Deyi Capital, Chongqing Pharscin Pharmaceutical Co., Ltd. CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chongqing Pharscin Pharmaceutical : Pharma to Unlock, List Restricted Shares MT
Chongqing Pharscin Pharmaceutical Co., Ltd.(XSEC:002907) dropped from S&P Global BMI Index CI
Chongqing Pharscin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Chongqing Pharscin Pharmaceutical Co., Ltd.(SZSE:002907) dropped from Shenzhen Stock Exchange Component Index CI
Chongqing Pharscin Pharmaceutical Co., Ltd.(SZSE:002907) dropped from Shenzhen Stock Exchange Component A Share Index CI
Chart Chongqing Pharscin Pharmaceutical Co., Ltd.
More charts
Chongqing Pharscin Pharmaceutical Co Ltd is a China-based company principally engaged in the research, development, production and sale of Chinese patent drugs and chemical drugs. The Company operates three segments: Pharmaceutical Industry segment, Commercial Circulation segment and Retail segment. The Company's products are categorized into the pharmaceuticals of digestive system, nervous system, otorhinolaryngology, cardiovascular and cerebrovascular systems and immune systems. The Company’s products include Weidimei (aluminum carbonate tablets), Ganju Bingmei Tablets, Bawei Qilong Particles, Liuwei Anshen Capsules, Sodium Ferulate for Injection, Omeprazole Sodium for Injection and Gabexate Mesilate for Injection. The Company mainly distributes its products in domestic market.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. 002907 Stock
  4. News Chongqing Pharscin Pharmaceutical Co., Ltd.
  5. Chongqing Pharscin Pharmaceutical : Pharma to Unlock, List Restricted Shares